Skip to main content
Terug
IDXX logo

IDEXX Laboratories, Inc.

Datakwaliteit: 100%
IDXX
NASDAQ Healthcare Medical - Diagnostics & Research
€ 570,21
▼ € 8,30 (-1,43%)
Marktkapitalisatie: 45,53B
Dagbereik
€ 565,33 € 576,51
52-Weeksbereik
€ 356,14 € 769,98
Volume
360.674
50D / 200D Gem.
€ 647,35 / € 635,19
Vorige Slotkoers
€ 578,51

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E 43,0 0,3
P/B 28,4 2,9
ROE % 66,2 3,7
Net Margin % 24,6 3,8
Rev Growth 5Y % 7,6 10,0
D/E 0,7 0,2

Koersdoel Analisten

Hold
€ 784,38 +37.6%
Low: € 730,00 High: € 830,00
Forward K/W
39,7
Forward WPA
€ 14,56
WPA Groei (sch.)
+0,0%
Omzet Sch.
4,7 B

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 26,21
€ 25,95 – € 26,56
7 B 6
FY2029 € 21,46
€ 21,24 – € 21,74
6,2 B 6
FY2028 € 18,75
€ 17,56 – € 19,89
5,6 B 8

Belangrijkste Punten

Revenue grew 7,56% annually over 5 years — modest growth
Earnings grew 19,33% over the past year
ROE of 66,20% indicates high profitability
Net margin of 24,62% shows strong profitability
Generating 1,05B in free cash flow
P/E of 42,98 — premium valuation

Groei

Revenue Growth (5Y)
7,56%
Revenue (1Y)10,42%
Earnings (1Y)19,33%
FCF Growth (3Y)16,75%

Kwaliteit

Return on Equity
66,20%
ROIC38,02%
Net Margin24,62%
Op. Margin31,60%

Veiligheid

Debt / Equity
0,67
Current Ratio1,17
Interest Coverage35,54

Waardering

P/E Ratio
42,98
P/B Ratio28,36
EV/EBITDA34,14
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 10,42% Revenue Growth (3Y) 8,42%
Earnings Growth (1Y) 19,33% Earnings Growth (3Y) 11,97%
Revenue Growth (5Y) 7,56% Earnings Growth (5Y) 9,21%
Profitability
Revenue (TTM) 4,30B Net Income (TTM) 1,06B
ROE 66,20% ROA 31,62%
Gross Margin 61,80% Operating Margin 31,60%
Net Margin 24,62% Free Cash Flow (TTM) 1,05B
ROIC 38,02% FCF Growth (3Y) 16,75%
Safety
Debt / Equity 0,67 Current Ratio 1,17
Interest Coverage 35,54 Dividend Yield 0,00%
Valuation
P/E Ratio 42,98 P/B Ratio 28,36
P/S Ratio 10,58 PEG Ratio 2,30
EV/EBITDA 34,14 Dividend Yield 0,00%
Market Cap 45,53B Enterprise Value 46,43B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 4,30B 3,90B 3,66B 3,37B 3,22B
Net Income 1,06B 887,87M 845,04M 679,09M 744,85M
EPS (Diluted) 13,08 10,67 10,06 8,03 8,60
Gross Profit 2,66B 2,38B 2,19B 2,00B 1,89B
Operating Income 1,36B 1,13B 1,10B 898,77M 932,03M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 3,35B 3,29B 3,26B 2,75B 2,44B
Total Liabilities 1,75B 1,70B 1,78B 2,14B 1,75B
Shareholders' Equity 1,61B 1,60B 1,48B 608,74M 689,99M
Total Debt 1,08B 986,95M 1,07B 1,47B 1,03B
Cash & Equivalents 180,07M 288,27M 453,93M 112,55M 144,45M
Current Assets 1,34B 1,40B 1,50B 1,10B 955,66M
Current Liabilities 1,15B 1,07B 951,55M 1,24B 763,58M